Correlation between clinical response to interleukin 2 and HLA phenotypes in patients with metastatic renal cell carcinoma
- PMID: 9010039
- PMCID: PMC2063266
- DOI: 10.1038/bjc.1997.46
Correlation between clinical response to interleukin 2 and HLA phenotypes in patients with metastatic renal cell carcinoma
Abstract
HLA phenotypes were characterized for 79 patients with metastatic renal cell carcinoma treated with interleukin 2 (IL-2). HLA-A32 was associated with a clinical response (P = 0.025). The frequency of HLA-A3 and/or A32 was higher among responders than non-responders (P = 0.008). Thus, these results suggest that, in vivo, IL-2 may enhance cellular-mediated immunity against a tumour antigen and that some MHC molecules are more efficient than others for endogenous tumour antigen presentation.
Similar articles
-
HLA phenotype and cytokine-induced tumor control in advanced renal cell cancer.Cancer Biother Radiopharm. 2001 Oct;16(5):401-9. doi: 10.1089/108497801753354302. Cancer Biother Radiopharm. 2001. PMID: 11776757
-
Carbon anhydrase IX specific immune responses in patients with metastatic renal cell carcinoma potentially cured by interleukin-2 based immunotherapy.Immunopharmacol Immunotoxicol. 2013 Aug;35(4):487-96. doi: 10.3109/08923973.2013.802802. Epub 2013 Jun 27. Immunopharmacol Immunotoxicol. 2013. PMID: 23802595 Clinical Trial.
-
Low-dose regimen of interleukin-2 for metastatic renal carcinoma.Lancet. 1990 Jun 23;335(8704):1522-3. doi: 10.1016/0140-6736(90)93057-v. Lancet. 1990. PMID: 1972445 No abstract available.
-
Interleukin-2 in the treatment of renal cell carcinoma and malignant melanoma.Cancer Treat Res. 2005;126:263-87. doi: 10.1007/0-387-24361-5_11. Cancer Treat Res. 2005. PMID: 16209070 Review. No abstract available.
-
Interleukin-2 therapy of metastatic renal cell carcinoma: update of phase III trials.Clin Genitourin Cancer. 2006 Sep;5(2):114-9. doi: 10.3816/CGC.2006.n.027. Clin Genitourin Cancer. 2006. PMID: 17026799 Review.
Cited by
-
Correlation of HLA-A02* genotype and HLA class I antigen down-regulation with the prognosis of epithelial ovarian cancer.Cancer Immunol Immunother. 2012 Aug;61(8):1243-53. doi: 10.1007/s00262-012-1201-0. Epub 2012 Jan 19. Cancer Immunol Immunother. 2012. PMID: 22258792 Free PMC article.
-
A pilot study in prostate cancer patients treated with the AE37 Ii-key-HER-2/neu polypeptide vaccine suggests that HLA-A*24 and HLA-DRB1*11 alleles may be prognostic and predictive biomarkers for clinical benefit.Cancer Immunol Immunother. 2015 Sep;64(9):1123-36. doi: 10.1007/s00262-015-1717-1. Epub 2015 May 31. Cancer Immunol Immunother. 2015. PMID: 26026288 Free PMC article. Clinical Trial.
-
The common Scandinavian human leucocyte antigen ancestral haplotype 62.1 as prognostic factor in patients with advanced malignant melanoma.Cancer Immunol Immunother. 2009 Oct;58(10):1599-608. doi: 10.1007/s00262-009-0669-8. Epub 2009 Feb 13. Cancer Immunol Immunother. 2009. PMID: 19214504 Free PMC article.
-
Are cytokine responses in renal cell cancer the product of placebo effect of treatment or true biotherapy? What trials are needed now?Br J Cancer. 1998 Apr;77(8):1318-20. doi: 10.1038/bjc.1998.219. Br J Cancer. 1998. PMID: 9579839 Free PMC article. Review. No abstract available.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials